Carbonic Anhydrase IX/CA9 Antibody

Immunohistochemistry-Paraffin: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - IHC analysis of a formain fixed paraffin embedded (FFPE) tissue section of human breast cancer using CAIX antibody at 1:1000 dilution. The primary antibody bound to CAIX antigens in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. This CAIX antibody generated an expected cytoplasmic staining of CAIX protein with an intense signal around the cellular membranes in tumor cores. The latter are more likely to be hypoxic in growing tumors which signifies that the observed CAIX staining is specific.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis in 1) HeLa, 2) MDA-MB-231 and 3) A549 whole cell lysates.

Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Immunofluorescence of human RCC tumor cryosections using NB100-417 (Panel A). Panel B shows staining with normal rabbit serum.

Immunohistochemistry-Frozen: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis of human colon carcinoma, xenografted in mice. Image courtesy of an anonymous product review.

Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis of HRP conjugate of NB100-417. HEK 293 cells using NB100-417. Panel A shows CAIX-transfected cells (epitope-unmasked with SDS) and panel B shows mock transfected cells.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis using the Biotin conjugate. Staining of Renal carcinoma tissue.

Simple Western: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Simple Western lane view shows a specific band for CAIX in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis using the HRP conjugate. Analysis in transfected HEK cell lysate. Rabbit IgG was used as a negative control.

Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis using the DyLight 488 conjugate of NB100-417. Staining of Carbonic Anhydrase IX (red) in human glioma U87 cells. DAPI counterstains nuclei (blue). Image provided via product review by verified customer.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Anaysis in transfected HEK cell lysate using NB 100-417. Rabbit IgG was used as a negative control.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis on rat renal cortex.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody [NB100-417] - Analysis on various human cell lysates. Image from verified customer review.

• Reactivity: Hu, Mu, Rt, Ca, Pl
• Applications: WB, Simple Western, ChIP, ELISA, Flow, GS, ICC/IF, IHC, IHC-Fr, IHC-P
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 1.0 mg/ml

Carbonic Anhydrase IX/CA9 Antibody Summary

• Immunogen: A synthetic peptide made to a C-terminal sequence of human Carbonic Anhydrase IX (within residues 400-459) [UniProt Q16790]
• Localization: Membrane.
• Marker: Hypoxia Marker
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CA9
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1:2000
  • Simple Western 1:50
  • Chromatin Immunoprecipitation 1:10-1:500
  • ELISA
  • Flow Cytometry
  • Gel Super Shift Assays
  • Immunocytochemistry/Immunofluorescence 1:1000
  • Immunohistochemistry 1:1000
  • Immunohistochemistry-Frozen 1:1000
  • Immunohistochemistry-Paraffin 1:1000
• Application Notes: This Carbonic Anhydrase IX antibody is useful for Western blot, Immunofluorescence/Immunocytochemistry, and Immunohistochemistry. Gel Super Shift Assays was reported in scientific literature. In Western blot a band is observed approx. 53 kDa. Use in ELISA reported in scientific literature (PMID 19963243). Use in chromatin immunoprecipitation reported in multiple pieces of scientific literature.
  
  In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. Separated by Size-Wes, Sally Sue/Peggy Sue.
  The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Positive Control:

  HeLa Lysate (NB800-PC1)
  Carbonic Anhydrase IX/CA9 Lysate (NBL1-08619)

• Control Peptide:

  Carbonic Anhydrase IX/CA9 Peptide (NB100-417PEP)

Reactivity Notes

Human, dog, rat and mouse (PMID 22842475). Plant reactivity reported in scientific literature (PMID: 19278636)

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.025% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for Carbonic Anhydrase IX/CA9 Antibody

• CA9
• CA-IX
• CAIXcarbonic anhydrase 9
• Carbonate dehydratase IX
• Carbonic Anhydrase IX
• carbonic anhydrase IXpMW1
• carbonic dehydratase
• EC 4.2.1.1
• G250
• Membrane antigen MN
• MN
• MNRCC-associated antigen G250
• P54/58N
• RCC
• RCC-associated protein G250
• Renal cell carcinoma-associated antigen G250

Background

Carbonic anhydrase IX (CAIX) is a member of the Carbonic anhydrase family which are enzymes that assists rapid interconversion of carbon dioxide and water into carbonic acid, protons, and bicarbonate ions. They are abundant in all mammalian tissues and because of their functionality, they have become an important diagnostic marker for various cancers, most notably renal cell carcinoma (RCC). Carbonic Anhydrase IX (CA IX) is one of the most hypoxically inducible genes because of its stability and the location of the expressed protein within the membrane. Carbonic anhydrases have a widespread role in regulating pH in normal tissues, by regulating hydrogen ion (H+) flux. The pH is important in cell death under hypoxia, thus a blockade of CA IX (CA9) results in increased cell death under hypoxia. Therefore, CA IX has become a reliable histochemical marker of hypoxia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Carbonic Anhydrase IX/CA9 Antibody (NB100-417)(145)

Publications using NB100-417

• Dreyer-Andersen N, Almeida AS, Jensen P et al. Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells PLoS ONE 2018 Jan 16 [PMID: 29338033] (ICC/IF, Human)
• Boyd NH, Walker K, Fried J et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017 Dec 21 [PMID: 29263302] (WB, Human)
• He L, Zhao C, Li Y et al. Antiangiogenic effects of recombinant human endostatin in lung cancers. Mol Med Rep. 2017 [PMID: 29115591] (Mouse)
• Nakamura M, Zhang Y, Yang Y et al. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. Proc. Natl. Acad. Sci. U.S.A. 2017 Oct 23 [PMID: 29078273] (Mouse)
• Wang D, Berglund AE, Kenchappa RS et al. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats Sci Rep 2017 Aug 24 [PMID: 28839258] (WB, Mouse)
• Bucau M, Laurent-Bellue A, Pote N et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation Neuroendocrinology 2017 Aug 11 [PMID: 28803235] (Human)
• Klameth L, Rath B, Hochmaier M et al. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance Sci Rep 2017 Jul 13 [PMID: 28706293] (IHC-P, Human)
• Zhang Y, Sun M, Huang G et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2017 Jun 27 [PMID: 28607065]
• Takenaka M, Suzuki N, Mori M et al. Iron regulatory protein 2 in ovarian endometrial cysts. Biochem. Biophys. Res. Commun. Apr 24 2017 [PMID: 28450115]
• Bousquet G, El Bouchtaoui M, Sophie T et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget. 2017 May 23 [PMID: 28445132] (ICC/IF, Human)
• Himmels P, Paredes I, Adler H et al. Motor neurons control blood vessel patterning in the developing spinal cord. Nat Commun. Mar 6 2017 [PMID: 28262664] (IHC-FR, Mouse)
• Eikrem OS, Strauss P, Beisland C et al. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing. Scand J Urol Dec 1 2016 [PMID: 27739342] (IHC, Human)
• Chen L, Chen L, Huang J et al. Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma: a morphometrical study of treatment effect. Int J Clin Exp Pathol. 2016 (IHC-P, Human)
• Fraga A, Ribeiro R, Coelho A et al. Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol 2017 Jan 31 [PMID: 28143503] (Human)
• Bulusu V, Tumanov S, Michalopoulou E et al. Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation Cell Rep Jan 17 2017 [PMID: 28099844] (IHC, Human)
• Tsuji T, Kurokawa Y, Chiche J et al. Dissecting the process of activation of cancer-promoting zinc-requiring ectoenzymes by zinc metalation mediated by ZnT transporters J. Biol. Chem Dec 27 2016 [PMID: 28028180] (WB)
• Oh ET, Kim JW, Kim JM et al. NQO1 inhibits proteasome-mediated degradation of HIF-1a. Nat Commun. Dec 14 2016 [PMID: 27966538] (IHC, Mouse)
• Frost J, Galdeano C, Soares P et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-alpha hydroxylation via VHL inhibition. Nat Commun. Nov 4 2016 [PMID: 27811928] (WB)
• Cauchy F, Mebarki M, Leporq B et al. Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clin. Sci. Nov 1 2016 [PMID: 27803295]
• Huang Y, Lichtenberger LM, Taylor M et al. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer Mol. Cancer Ther. Sep 16 2016 [PMID: 27638860] (IHC, Human)
• Kim En, Kim Gh, Kim J et al. A Pyloric Gland-Phenotype Ovarian Mucinous Tumor Resembling Lobular Endocervical Glandular Hyperplasia in a Patient with Peutz-Jeghers Syndrome. J Pathol Transl Med Aug 22 2016 [PMID: 27550049] (IHC-P)
• van Kuijk SJ, Gieling RG, Niemans R et al. The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS ONE. Aug 12 2016 [PMID: 27513947] (IHC, Human)
• Hirakawa T, Yashiro M, Doi Y et al. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia. PLoS ONE. Aug 4 2016 [PMID: 27487118] (IHC, Human)
• Yoon C, Chang KK, Lee JH et al. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1a inhibition, and hypoxia-activated chemotherapy Oncotarget Jul 12 2016 [PMID: 27374091] (Mouse)
• Leek R, Grimes DR, Harris AL, McIntyre A. Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia. Adv. Exp. Med. Biol. Jun 21 2016 [PMID: 27325267] (IHC, Human, Mouse)
• He H, Yang Y, Xiang Z et al. A Sensitive IHC Method for Monitoring Autophagy-Specific Markers in Human Tumor Xenografts. J Biomark. Jun 1 2016 [PMID: 27247826] (IHC-P, Human)
• Hecht JL, Zsengeller ZK, Spiel M, Karumanchi SA. Revisiting decidual vasculopathy. Placenta. 2016 Apr 08 [PMID: 27238712] (IHC-P, Human)
• Xu W, Ghosh S, Comhair SA et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. J. Clin. Invest. May 23 2016 [PMID: 27214549] (IHC-P, Mouse)
• Badar T, Handisides DR, Benito JM et al. A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia. Am. J. Hematol. May 11 2016 [PMID: 27169385] (IHC-P, Human)
• Faes S, Planche A, Uldry E et al. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. Oncotarget. Jun 14 2016 [PMID: 27153561] (IHC, Mouse)
• Ono M, Yamada K, Bensaddek D et al. Enhanced snoMEN Vectors Facilitate Establishment of GFP-HIF-1alpha Protein Replacement Human Cell Lines. PLoS ONE. Apr 30 2016 [PMID: 27128805] (WB, Human)
• Eikrem O, Beisland C, Hjelle K et al. Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development PLoS ONE Feb 23 2016 [PMID: 26901863] (IHC-P, Human)
• Radoul M, Chaumeil MM, Eriksson P et al. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. Mol. Cancer Ther. May 1 2016 [PMID: 26883274] (IHC, Mouse)
• Scholz A, Harter PN, Cremer S et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2016 Jan 05 [PMID: 26666269] (IHC-P, Human)
• Mitsuhashi A, Goto H, Saijo A et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun. 2015 Dec 04 [PMID: 26635184] (IHC-Fr, Mouse)
• Andre H, Tunik S, Aronsson M, Kvanta A. Hypoxia-Inducible Factor-1alpha Is Associated With Sprouting Angiogenesis in the Murine Laser-Induced Choroidal Neovascularization Model. ARVO Journals. 2015 Oct [PMID: 26501235] (ICC/IF, Mouse)
• Klier M, Jamali S, Ames S et al. Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly. FEBS J 2016 Jan [PMID: 26470855]
• Islam SS, Mokhtari RB, Akbari P et al. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN). Target Oncol 2015 Oct 10 [PMID: 26453055]
• Kinoshita H, Yashiro M, Fukuoka T et al. Diffuse-type Gastric Cancer Cells Switch Their Driver Pathways from FGFR2 Signaling to SDF1/CXCR4 Axis in Hypoxic Tumor Microenvironments. Carcinogenesis 2015 Sep 18 [PMID: 26385890] (IHC-P, Mouse)
• Jamali S, Klier M, Ames S et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep 2015 Sep 04 [PMID: 26337752] (WB, ICC/IF, Human)
• Baine MK, Turcu G, Zito CR et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015 Sep 22 [PMID: 26317902]
• Song CW, Lee YJ, Griffin RJ et al. Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. Int J Radiat Oncol Biol Phys 2015 Sep 1 [PMID: 26279032]
• Ward C, Meehan J, Mullen P et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models Oncotarget 2015 Jul 04 [PMID: 26259239]
• Kasashima H, Yashiro M, Kinoshita H et al. Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia. Gastric Cancer 2016 Apr [PMID: 26100130]
• Yoon C, Lee HJ, Park DJ et al. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br. J. Cancer. 2015 May 26 [PMID: 26010414] (IHC-P, ICC/IF, Human)
• Dulloo I, Phang BH, Othman R et al. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nat. Cell Biol. 2015 Apr 01 [PMID: 25774835] (IHC-P, Human)
• Cotroneo E, Ashek A, Wang L et al. Iron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Rat. Circ. Res. 2015 Mar 12 [PMID: 25767292] (IHC, Rat)
• Kang HJ, Kim IH, Sung CO et al. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma Virchows Arch. 2015 Jan 11 [PMID: 25577552] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used at 1:1000 dilution for IHC-P staining on formalin-fixed, paraffin-embedded tissue sections/TMAs created from surgically resected hepatocellular carcinoma/HCC and adjacent non-neoplastic liver tissue - 32 minutes of heat-induced epitope retrieval with Cell Conditioning 1 /CC1 buffer, 16 minutes of primary antibody incubation on Ventana's autoimmunostainer/Bench Mark XT automatic immunostaining device, staining development with Ventana's OptiView DAB IHC Detection Kit. Fig 2a-f documents the staining images showing weak, moderate and strong membranous expression levels of carbonic anhydrase 9 protein and the overall data in this study establishes CA9 protein as a poor prognostic factor in resectable HCC patients.
• Mudie S, Bandarra D, Batie M et al. PITX1, a specificity determinant in the HIF-1alpha-mediated transcriptional response to hypoxia. Cell Cycle 2014 [PMID: 25558831] (WB)
• Lee H, Yoon C, Park DJ et al. Inhibition of Vascular Endothelial Growth Factor A and Hypoxia-Inducible Factor 1alpha Maximizes the Effects of Radiation in Sarcoma Mouse Models Through Destruction of Tumor Vasculature. Int. J. Radiat. Oncol. Biol. Phys. 2014 Dec 24 [PMID: 25544668]
• Janmohamed SR, Brinkhuizen T, den Hollander JC et al. Support for the hypoxia theory in the pathogenesis of infantile haemangioma. Clin. Exp. Dermatol. 2014 Dec 16 [PMID: 25511669] (IHC-P, Human)
• Lin XY, Zhang H, Tang N et al. Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology. Histopathology. 2014 Nov 27 [PMID: 25431204] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used for IHC-P on sections of clear cell renal cell carcinoma (ccRCC; primary and metastatic) and several other type of tumors with predominantly clear cell morphology - tissues previously fixed in 10% neutral buffered formalin and embedded in paraffin, 4um sections, routine IHC-P processing with streptavidin-peroxidase detection system. ccRCC, and breast / pulmonary/hepatic clear cell carcinoma, urothelial carcinoma with clear cell change, clear cell meningioma/ependymoma, haemangioblastoma, and clear cell hidradenoma showed expression of CAIX. See full text for staining images and the expression levels.
• Gellert LL, Mehra R, Chen YB et al. The diagnostic accuracy of percutaneous renal needle core biopsy and its potential impact on the clinical management of renal cortical neoplasms. Arch. Pathol. Lab. Med. 2014 Dec 01 [PMID: 25427045] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used for IHC-P on sections of human renal biopsies having sarcomatoid area with focal necrosis and clear cell renal cell carcinoma (Figure 3.).
• Santos Cd, Tijeras-Raballand A, Serova M et al. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. Br. J. Cancer. 2014 Nov 25 [PMID: 25422908] (IHC-P, Human)
• Hwa JS, Kwon OJ, Park JJ et al. The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014 Aug 29 [PMID: 25169079]
• Chen LQ, Howison CM, Spier C et al. Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk. Lymphoma. 2014 Aug 17 [PMID: 25130478]
• Motzer RJ, Hutson TE, Hudes GR et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother. Pharmacol. 2014 Aug 07 [PMID: 25100134] (IHC-P, Human)
  
  Details:
  Rabbit polyclonal Carbonic Anhydrase IX/CA-IX antibody used for IHC on formalin-fixed paraffin-embedded (FFPE) blocks or unstained slides from tumor specimens.
• Sadlecki P, Bodnar M, Grabiec M. The Role of Hypoxia-Inducible Factor-1a, Glucose Transporter-1,(GLUT-1) and Carbon Anhydrase IX in Endometrial Cancer Patients. BioMed Research International 3/12/2014 [PMID: 24745019] (IHC-P, Human)
• Heijmen L, Voert EGW, Punt CJA. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging 2014 May-Jun [PMID: 24700751] (IHC-Fr, Human)
  
  Details:
  Using the Biotin conjugated version of NB100-417, catalog number NB100-417B.
• Kwon OJ, Park JJ, Ko GH et al. HIF-1a and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma. Head Neck 2/12/2014 [PMID: 24677746] (IHC-P, Human)
• Chen X, Iliopoulos D, Zhang Q et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1a pathway. Nature 4/3/2014 [PMID: 24670641] (IHC-P, Human)
• Morifuji Yoshihiro, Onishi Hideya, Iwasaki Hironori et al. Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. Cancer Sci. 2014 Feb 11 [PMID: 24397700]
• Polanski Radoslaw, Hodgkinson Cassandra L, Fusi Alberto et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014 Feb 15 [PMID: 24277449] (IHC)
• Pinato DJ, Tan TM, Toussi ST et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2013 Nov 14 [PMID: 24231952] (IHC-P, Human)
• Chaudary N, Pintilie M, Schwock J et al. Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers (Basel) 2012 [PMID: 24213469] (IHC)
• Zhang M, Boughton P, Rose B et al. The Use of Porous Scaffold as a Tumor Model. Int J Biomater. 2013 [PMID: 24101930] (IHC, Human)
• Wen YA, Stevens PD, Gasser ML et al. Downregulation of PHLPP Expression Contributes to Hypoxia-Induced Resistance to Chemotherapy in Colon Cancer Cells. Mol Cell Biol. 2013 Nov [PMID: 24061475] (WB, Human)
• El-Heliebi A, Kroneis T, Zohrer E et al. Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?. J Transl Med. 2013 Sep 17 [PMID: 24044779] (ICC/IF, Human)
• Fahling M, Mathia S, Paliege A et al. Tubular von Hippel-Lindau Knockout Protects against Rhabdomyolysis-Induced AKI. J Am Soc Nephrol. 2013 Aug 22 [PMID: 23970125]
• Cioffi S, Martucciello S, Fulcoli FG et al. Tbx1 regulates brain vascularization. Hum Mol Genet. 2013 Sep 7 [PMID: 23945394] (IHC-Fr, ICC/IF, Mouse)
• Kumar S, Mokhtari RB, Oliveira ID et al. Tumor Dynamics in Response to Antiangiogenic Therapy with Oral Metronomic Topotecan and Pazopanib in Neuroblastoma Xenografts. Transl Oncol 2013 Aug 1 [PMID: 23908692] (IHC, Human)
• Dubois L, Peeters SG, van Kuijk SJ et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiother Oncol 2013 Jul 9 [PMID: 23849171] (IHC-Fr, Mouse)
• Campanile C, Arlt MJ, Kramer SD et al. Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models. J Nucl Med 2013 Jun 25 [PMID: 23801674]
• Bussolati B, Lauritano C, Moggio A et al. Renal CD133+/CD73+ Progenitors Produce Erythropoietin under Hypoxia and Prolyl Hydroxylase Inhibition. J Am Soc Nephrol 2013 May 9 [PMID: 23661806]
• Carbonell WS, Delay M, Jahangiri A et al. beta1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma. Cancer Res 2013 May 15 [PMID: 23644530] (IHC-P, ICC/IF, Human)
• Cho SY, Lee HJ, Lee HJ et al. Activation of AMP-Activated Protein Kinase alpha and Extracelluar Signal-Regulated Kinase Mediates CB-PIC-Induced Apoptosis in Hypoxic SW620 Colorectal Cancer Cells Evid Based Complement Alternat Med 2013 [PMID: 23589723] (IHC-P, Human)
• Aarntzen EH, Srinivas M, Bonetto F et al. Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clin Cancer Res 2013 Mar 15 [PMID: 23382117] (IHC, Human)
• Zhang Q, Bai X, Chen W et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013 Jan 27 [PMID: 23358852] (WB, Human)
• Heijmen L, Punt CJ, Ter Voert EG et al. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Invest New Drugs 013 Jan 17 [PMID: 23325291] (IHC, ICC/IF, Mouse)
  
  Details:
  Using the Biotin conjugated version of NB100-417, catalog number NB100-417B.
• Pinato DJ, Ramachandran R, Toussi ST et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations Br J Cancer 2012 Dec 20 [PMID: 23257898] (IHC, Human)
• Delhaas T, Van der Meer SF, Schaart G et al. Steep Increase in Myonuclear Domain Size During Infancy Anat Rec (Hoboken) 2012 Dec 4 [PMID: 23213045] (IHC, ICC/IF, Human)
• Proescholdt MA, Merrill MJ, Stoerr EM et al. Function of carbonic anhydrase IX in glioblastoma multiforme Neuro Oncol 2012 Nov [PMID: 23074198] (IHC, WB, Human)
• Currie MJ, Beardsley BE, Harris GC et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity Hum Pathol 2012 Oct 1 [PMID: 23036368] (IHC, Human)
• Piao Y, Liang J, Holmes L et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype Neuro Oncol 2012 Sep 10 [PMID: 22965162] (IHC, Human, Mouse)
• Muriel Lopez C, Esteban E, Berros JP et al. Prognostic Factors in Patients With Advanced Renal Cell Carcinoma Clin Genitourin Cancer 2012 Sep 6 [PMID: 22959659] (IHC, Human)
• Brouillet S, Murthi P, Hoffmann P et al. EG-VEGF controls placental growth and survival in normal and pathological pregnancies: case of fetal growth restriction (FGR) Cell Mol Life Sci 2012 Sep 2 [PMID: 22941044] (IHC, Human)
• Engler JR, Robinson AE, Smirnov I et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas PLoS One 2012 [PMID: 22937035] (IHC, Human)
• Yin S, Kaluz S, Devi NS et al. Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1alpha Interaction with Cofactors p300/CBP Clin Cancer Res 2012 Dec 15 [PMID: 22923450] (WB, Human)
• Park I, Hu S, Bok R et al. Evaluation of heterogeneous metabolic profile in an orthotopic Human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2013 Jul [PMID: 22851374] (IHC-P, Rat)
• Fromy B, Lingueglia E, Sigaudo-Roussel D et al. Asic3 is a neuronal mechanosensor for pressure-induced vasodilation that protects against pressure ulcers Nat Med 2012 Jul 29 [PMID: 22842475] (IHC, Mouse)
• Eguchi D, Ikenaga N, Ohuchida K et al. Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor J Surg Res 2012 Jul 6 [PMID: 22795353] (IHC, Human)
• Albert S, Hourseau M, Halimi C et al. Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol 2012 Dec [PMID: 22776129]
• Muriel Lopez C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M, Martinez-Camblor P. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs. 2012 May 27. [PMID: 22644070] (IHC, Human)
• Pellegrini L, Pucci B, Villanova L, Marino ML, Marfe G, Sansone L, Vernucci E, Bellizzi D, Reali V, Fini M, Russo MA, Tafani M. SIRT3 protects from hypoxia and staurosporine-mediated cell death by maintaining mitochondrial membrane potential and intracellular pH. Cell Death Differ. 2012 May 18. [PMID: 22595756] (WB, Human)
• Weber DC, Tille JC, Combescure C et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy Radiat Oncol 2012 Apr 30 [PMID: 22546016] (IHC, Human)
• Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci. 2012 Apr 6. [PMID: 22486854] (IHC, ICC/IF, Mouse)
• Speisky D, Duces A, Bieche I et al. Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. Clin Cancer Res;18(10):2838-2849. 2012 May 15. [PMID: 22461457] (IHC, Human)
• Matsumura Y, Ishii G, Aokage K, Kuwata T, Hishida T, Yoshida J, Nishimura M, Nagai K, Ochiai A. Morphophenotypic characteristics of intralymphatic cancer and stromal cells susceptible to lymphogenic metastasis. Cancer Sci. 2012 Mar 16. [PMID: 22429811] (IHC, Human)
• Wang Y, Roche O, Xu C et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1 Proc Natl Acad Sci U S A 2012 Mar 12 [PMID: 22411794] (EMSA, WB, Human)
• Lim CS, Kiriakidis S, Paleolog EM, Davies AH. Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg;55(5):1427-1439e1. 2012 May. [PMID: 22277691] (WB, Human)
• Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, Bedossa P, Ruszniewski P, Couvelard A. The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum. Neuroendocrinology. 2011 Nov 29. [PMID: 22133596] (IHC, Human)
• Jung JH, Kim HJ, Yeom J, Yoo C, Shin J, Yoo J, Kang CS, Lee C. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol;47(1):37-48. 2012 Jan. [PMID: 22015694] (WB, Human)
• Guise CP, Abbattista MR, Tipparaju SR et al. Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR104A Under Hypoxia. Molecular Pharmacology. 2011 Oct 7. [PMID: 21984255]
• Ogino T, Onishi H, Suzuki H et al. Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. Cancer Immunology, Immunotherapy: CII. 2011 Sep 20. [PMID: 21932134]
• Melvin A, Mudie S, Rocha S. The chromatin remodeler ISWI regulates the cellular response to hypoxia, role of FIH. Mol Biol Cell. 2011 Sep 7. [PMID: 21900490] (Human)
• Benito J, Shi Y, Szymanska B et al. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS ONE. 2011 [PMID: 21853076]
• Garcia-Parra R, Wood D, Shah RB et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by (18)F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging. 2011 Jul 16. [PMID: 21833840] (IHC-P, Human)
• Chaumeil MM, Ozawa T, Park I et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. NeuroImage. [PMID: 21807103] (IHC-P, Rat)
• Chamboredon S, Ciais D, Desroches-Castan A et al. Hypoxia-inducible Factor-1{alpha} mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Mol Biol Cell. 2011 Jul 20. [PMID: 21775632] (WB, Human)
• Al-Ahmadie HA, Alden D, Fine SW et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am. J. Surg. Pathol. 2011 Jul. [PMID: 21677535] (IHC, Human)
• Mackenzie KA, Miller AP, Hock BD, Gardner J, Simcock JW, Roake JA, Dachs GU, Robinson BA, Currie MJ. Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology;58(6):875-85. 2011 May. [PMID: 21585427] (IHC, Human)
• Nelson MP, Christmann BS, Werner JL et al. IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J Immunol 2011 Feb 15 [PMID: 21220696] (ChIP)
• Li Y, Wang H, Tu C et al. Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells. Biochim Biophys Acta. 2010 Oct 1. [PMID: 20920536] (WB, Human)
• Lapinski JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers. Appl Immunohistochem Mol Morphol;18(5):414-21. 2010 Oct. [PMID: 20861762] (IHC, Human)
• Newton IP, Kenneth NS, Appleton PL et al. Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell 2010 Nov 1 [PMID: 20844082] (ChIP)
• Pistollato F, Rampazzo E, Persano L et al. Interaction of hypoxia-inducible factor-1a and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 2010 Nov [PMID: 20827750] (IHC-P, Human)
• Kato Y, Yashiro M, Noda S et al. Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010 [PMID: 20588040] (IHC, Human)
• O'Toole D, Couvelard A, Rebours V et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010 Dec [PMID: 20570957] (IHC, Human)
• Stillebroer AB, Mulders PF, Boerman OC et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010 Jul [PMID: 20359812]
• Pistollato F, Abbadi S, Rampazzo E et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010 May [PMID: 20309962] (IHC-P, Human)
• Park I, Larson PE, Zierhut ML et al. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010 Feb [PMID: 20150380] (IHC)
• Arvidsson Y, Bergstrom A, Arvidsson L et al. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer 2010 Jun 1 [PMID: 20071457] (IHC, Human)
• Zhou GX, Ireland J, Rayman P et al. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 2010 Feb [PMID: 19963243] (ELISA, Human)
• Narita T, Yin S, Gelin CF et al. Identification of a Novel Small Molecule HIF-1{alpha} Translation Inhibitor. Clin Cancer Res 9;15(19):6128-6136. 200 [PMID: 19789328] (WB, Human)
• Hong YS, Cho HJ, Kim SY et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009 [PMID: 19619339] (IHC, Human)
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of Glioblastoma Resistance Invasion during Antivascular Endothelial Growth Factor Therapy. Clin Cancer Res:1078-0432.CCR-1009-0575. 2009 [PMID: 19567589] (IHC-P, Human)
• Loinard C, Ginouves A, Vilar J et al. Inhibition of Prolyl Hydroxylase Domain Proteins Promotes Therapeutic Revascularization. Circulation;120(1):50-59. 2009 [PMID: 19546390] (WB, Human, Mouse)
• Li Y, Wang H, Oosterwijk E et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 2009 Aug 28 [PMID: 19538935] (IHC-P, Human)
• Chen J, Kobayashi M, Darmanin S et al. Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation. Am J Pathol;175(1):400-411. 2009 [PMID: 19528349] (IHC-P, Mouse)
• Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009 May 15 [PMID: 19402057] (Human)
• Banuelos CA, Banath JP, Kim J-Y et al. {gamma}H2AX Expression in Tumors Exposed to Cisplatin Fractionated Irradiation. Clin Cancer Res;15(10):3344-3353. 2009 [PMID: 19401347] (IHC-P, Human)
• Nakao M, Ishii G, Nagai K et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009 Jun 15 [PMID: 19365853] (WB, Human)
• Dumais J. Plant morphogenesis: a role for mechanical signals. Curr Biol 2009 Mar 10 [PMID: 19278636] (IHC, Plant)
• Bachmann IM, Ladstein RG, Straume O et al. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 2008 [PMID: 19061491] (IHC, Human)
• Skapa P, Hyrsl L, Zavada J et al. Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component. J Clin Oncol 2008 Aug 1 [PMID: 18669473] (Human)
• Sakata K, Someya M, Nagakura H et al. Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers. Jpn J Clin Oncol;38(6):402-7. 2008 Jun. [PMID: 18573850] (IHC-P, Human)
• Al-Ahmadie HA, Alden D, Qin LX et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008 Mar [PMID: 18300814] (IHC, Human)
• Baia GS, Dinca EB, Ozawa T et al. An orthotopic skull base model of malignant meningioma. Brain Pathol 2008 Apr [PMID: 18093250] (IHC-P, Mouse)
• Gauter-Fleckenstein B, Fleckenstein K, Owzar K et al. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med 2008 Mar 15 [PMID: 18082148] (IHC-P, Rat)
• Kaidi A, Moorghen M, Williams AC et al. Is the downregulation of EphB2 receptor expression during colorectal tumorigenesis due to hypoxia?. Gut 56(11):1637-8. 2007 Nov. [PMID: 17938437] (IHC-P, Human)
• Westbury CB, Pearson A, Nerurkar A et al. Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. Br J Radiol;80(959):934-8. 2007 Nov. [PMID: 17908818] (IHC-P, Human)
• Yoo H, Baia GS, Smith JS et al. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res;13(1):68-75. 2007 Jan 1. [PMID: 17200340] (IHC-P, Human)
• Van den Eynden GG, Van der Auwera I, Van Laere SJ et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer;93(10):1128-36. 2005 Nov 14. [PMID: 16251878] (IHC-P, Human)
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res;11(10):3714-21. 2005 May 15. [PMID: 15897568] (IHC, Human)
• Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol;26(2):271-8. 2008 Jan 10. [PMID: 1818266] (IHC-P, Human)

Reviews for Carbonic Anhydrase IX/CA9 Antibody (NB100-417) (4)

Average Rating: 4.5

(Based on 4 reviews)

We have 4 reviews tested in 2 species: Human, Mouse.

reviewed by: Anonymous IHC-P Mouse 10/25/2017

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: IHC on parrafin sections (mouse)
• Species: Mouse
• Lot: AD-1

reviewed by: rajesha rupaimoole WB Human 12/10/2014

Summary

• Application: Western Blot
• Sample Tested: A2780 ovarian cancer cells
• Species: Human

Blocking

• Blocking Details: 5% BSA

Details

• Detection Notes: ECL

reviewed by: Xiuquan Luo WB Human 07/21/2014

Summary

• Application: Western Blot
• Sample Tested: 20 ug whole cell lysate
• Species: Human

Blocking

• Blocking Details: 1xPBST with 5% non-fat milk, RT 1 hour

Primary Anitbody

• Dilution Ratio: 1xpBST with 5% non-fat milk, overnight 4C, 1:1000 dilution

Secondary Antibody

• Secondary Description: Goat anti-rabbit IgG-HRP
• Secondary Manufacturer Cat#: sc-2004
• Secondary Concentration: 1:2000 dilution

Details

• Detection Notes: ECL, exposured for 3 min

reviewed by: Sonia Rocha ICC Human 12/21/2011

Summary

• Application: Immunocytochemistry
• Sample Tested: Human cells
• Species: Human
• Comments: Really nice results using microscopy.

Blocking

• Blocking Details: Blocking Buffer: 1% Donkey serum PBS, Blocking Time: 30 minutes, Blocking Temp: 20 degrees Celsius

Primary Anitbody

• Dilution Ratio: Incubation Dilution Buffer: PBS/1% Donkey serum, Dilution Ratio: 1:250, Incubation Time: 1 hour, Incubation Temp: 20 C

Secondary Antibody

• Secondary Description: Secondary Ab: anti-rabbit alexa 488, Secondary Ab Dilution: 1:500

Details

• Detection Notes: Detection Visualization Method: fluorescence at 488, Negative Control: secondary and primary only
• Fixation Details: Sample Preparation: PFA fixed

Comments

• Comments: Really nice results using microscopy.

FAQs for Carbonic Anhydrase IX/CA9 Antibody (NB100-417). (Showing 1 - 8 of 8 FAQs).

1. How many units do we need to purchase in order to stain 150 formalin fixed, paraffin embedded kidney biopsies? It depends on the amount used per slide, so could you please confirm how much antibody do you use per slide in IHC-P? Also, is the ab compatible with ENVISION FLEX+, HIGH pH, FOR AS?
   • Unfortunately there is no number that I can provide to you as it is impossible to know for sure how many slides you will be able to stain with a vial. This will depend on your experimental conditions, your samples and how highly expressed the protein is, and what dilution you end up choosing. This antibody is recommended to be used at a 1:1000 dilution for IHC staining as this has worked well for our lab. You should order a single vial and test to determine what amount will be best for your assay rather than order too much or too little without first working with the antibody. As for your second question, that is not something that our lab has tested with so I am unsure if it is compatible or not. It has a fairly normal range pH in the buffer (7-8) so most likely the functions best around that range and not at a high pH.
2. Could you please let me know the immunogen peptide location for this Ab?
   • The immunogen used to create this antibody was made to a cytoplasmic area of the protein.
3. I'm going to use your CA-9 Antibody for paraffin-Immunohistochemistry. Do I have to do any special pretreatments?
   • Here is our protocol specific for this product. However, we recommend antigen retrieval to ensure the epitope is not masked, and we also recommend that you add a permeablizing agent to access the epitope in the nucleus.
4. We dilute our antibodies in 5% milk TBS-Tween and usually freeze-thaw them multiple times. Is this possible with this antibody when diluted?
   • Freezing is not recommended for NB100-417 under any circumstances. Unfortunately, the antibody would no longer be covered by our guarantee if it was stored at a temperature that did not match our storage instructions. Of course, you are free to test your proposed conditions if you would like, but we would not be able to accept responsibility if the antibody was damaged by this.
5. Is this antibody is carrier-free? If not, do you have a carrier-free version?
   • NB100-417 is carrier protein free, but does contain 0.1% sodium azide. The buffer formulation is: Tris-citrate/phosphate, pH 7-8 with 0.1% sodium azide. The following products are carrier protein and azide free (catalog numbers 23300002, H00000768-B01P and H00000768-D01P). If you would like to use NB100-417, we do offer antibody purification kits to remove unwanted buffer ingredients. See this link here for those products.
6. I have a couple of questions regarding the Carbonic Anhydrase IX Antibody (NB100-417) listed on your website. We are wondering if this antibody is carrier-free, and if not, whether you have a carrier-free version?
   • Our NB100-417 is carrier protein free but does contain 0.1% sodium azide. The buffer formulation is: Tris-citrate/phosphate, pH 7-8 with 0.1% sodium azide. The following products are carrier protein and azide free (catalog numbers 23300002, H00000768-B01P and H00000768-D01P). If you would like to use NB100-417, we do offer antibody purification kits to remove unwanted buffer ingredients. See the link here for those products: AbSelect.
7. I am interested in using the CA9 antibody (NB100-417) that you supply. We dilute our antibodies in 5% milk TBS-Tween and usually freeze-thaw them multiple times. Is this possible with this antibody when diluted?
   • I have checked with the lab and they have informed me that freezing is not recommended for NB100-417 under any circumstances. Unfortunately, the antibody would no longer be covered by our guarantee if it was stored at a temperature that did not match our storage instructions. Of course, you are free to test your proposed conditions if you would like, but we would not be able to accept responsibility if the antibody was damaged by this.
8. Could this antibody (CA9) be safely stored at -80C?
   • The recommended storage temperature for NB100-417 is -20C. It may be possible to store this antibody at -80C, but this has not been confirmed by our lab. It is most important to ensure that that antibody does not undergo too many freeze-thaw cycles.

Bioinformatics

• Gene Symbol: CA9
• Entrez:
  • 768(Human)
  • 230099(Mouse)